Berenberg raises target price on Convatec.

Analysts at Berenberg raised their target price on medical device firm Convatec Group from 310.0p to 335.0p on Friday as it pointed to "good momentum" ahead of the company's interim results.

Convatec Group
27 June 2025 11:14:15

Source: Sharecast

Berenberg noted that Convatec's shares had "a strong first half", up 32% year-to-date, and have benefited from continued progress across all of its segments, as well as delays to the implementation of local coverage determinations in wound care.

However, the German bank noted that even with the re-rating in the shares, Convatec trades on an "undemanding" 12.0x FY26 enterprise value/underling earnings ratio, despite mid-teens earnings growth estimated for 2025-27.

"Looking ahead, the company's trading update on 22 May suggests momentum in the business is strong ahead of H1 results on 29 July," said Berenberg. "As a result, we could see further upside to earnings expectations as we move through the year."

Berenberg also reiterated its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

FTSE 100 ( UKX )

ISIN: N/A

Exchange: London Stock Exchange

Sell:

0.00

Buy:

0.00

Change: 63.31 ( 0.72 %)

Date:

27/06/2025 - 16:59

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.